HER2 In Situ Hybridization: Validation and Implementation of Brightfield Assay in a US Academic Pathology Laboratory
{{output}}
Assessment of HER2 overexpression and gene (ERBB2) amplification remains an essential predictive test that determines tailored breast cancer therapy. Based on institutional needs, we recently validated the VENTANA HER2 Dual ISH DNA Probe Cocktail assay (DISH).... ...
